Renata Medical closed a $25M Series D on August 19, 2026. ARCHIMED, a healthcare-only investment firm, led, and existing investors participated. Co-founder and CEO Dustin Armer said the funds go to expanded US commercialization and entry into international markets. They also support the pediatric congenital heart pipeline and clinical evidence.
Minima is a balloon-expandable growth stent designed for the smallest patients. It is indicated for pulmonary artery stenosis and coarctation of the aorta in neonates, infants and young children. FDA approved it under PMA P240003 on August 28, 2024, product code PNF, and the company launched the same year. CMS granted a New Technology Add-on Payment in August 2025. openFDA shows seven supplements since approval, including the Minima Pro Stent System approved under S006 on July 9, 2026.
The Newport Beach, CA company was founded in 2019 and had a pediatric PMA approved within five years. Pediatric structural heart is a small market most large companies skip. The NTAP is what makes a $25M commercial round pencil out at these volumes.